Targeting the Plasmodium Ubiquitin/Proteasome System with Anti- Malarial Compounds: Promises for the Future

E-ISSN： 2212-3989|10|3|158-164

ISSN： 1871-5265

Source： Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders), Vol.10, Iss.3, 2010-06, pp. : 158-164

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting the ubiquitin-proteasome system for cancer therapy

By Shen Min

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 9, 2013-09 ,pp. : 1091-1108

Informa Healthcare

Access to resources Recommend Favorite

Overview of Proteasome Inhibitor-Based Anti-cancer Therapies: Perspective on Bortezomib and Second Generation Proteasome Inhibitors versus Future Generation Inhibitors of Ubiquitin-Proteasome System

Current Cancer Drug Targets, Vol. 14, Iss. 6, 2014-07 ,pp. : 517-536

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition

Current Pharmaceutical Design, Vol. 19, Iss. 22, 2013-01 ,pp. : 4053-4093

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial(Hot Topic:Targeting the Ubiquitin-Proteasome Pathway - Current Perspectives and Future Directions)

Current Pharmaceutical Design, Vol. 19, Iss. 18, 2013-06 ,pp. : 3173-3174

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-Parkinsonian Effects of Nurr1 Activator in Ubiquitin-Proteasome System Impairment Induced Animal Model of Parkinson’s Disease

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 11, Iss. 6, 2012-09 ,pp. : 768-773

Bentham Science Publishers

Access to resources Recommend Favorite